MENU

Fox Chase Cancer Center News

July 13, 2021

Fox Chase Receives NIH Grant to Fund Study of Stem Cell Responses to Nutrition

PHILADELPHIA (July 13, 2021)—Researchers at Fox Chase Cancer Center have received a grant to study how stem cells in the ovary respond to nutrition, particularly in ways that mirror certain cancers.

July 13, 2021

Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

PHILADELPHIA (July 13, 2021)– Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Fox Chase Cancer Center in Philadelphia, PA, has been added as an active trial site for the dose-expansion stage of the ongoing clinical trial evaluating the company’s lead drug candidate, seclidemstat, in patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas.

July 8, 2021

Historic Discovery of ThPOK Gene Honored in Journal Retrospective

PHILADELPHIA (July 8, 2021) — The white blood cells called T-cells play a critical role in immune function. However, for many years, scientists didn’t know why these cells divided into so-called CD8 “killer” T-cells, which fight and destroy pathogens, and CD4 “helper” T-cells, which play a supporting role by triggering the body’s wider immune response.

July 8, 2021

Head and Neck Cancer Survivors Could Benefit From Interdisciplinary Survivorship Clinic

PHILADELPHIA (July 8, 2021) — Survivors of head and neck cancers might benefit from an interdisciplinary survivorship clinic that includes assessment and screening by rehabilitation specialists, according to Fox Chase Cancer Center researchers.

July 8, 2021

Report Recommends Mechanical Removal for Treating Adults With Tumors Caused by Recurrent Respiratory Papillomatosis

PHILADELPHIA (July 8, 2021) — Mechanical removal is safer than more traditional methods of burning or ablating tumors that arise from recurrent respiratory papillomatosis (RRP), a respiratory disease caused by the human papilloma virus, according to the findings of a case series published recently by researchers at Fox Chase Cancer Center.

July 7, 2021

Sanjeevani Arora Receives Yale Head and Neck SPORE Career Enhancement Program Award

PHILADELPHIA (July 7, 2021) - Sanjeevani Arora, PhD, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received the Yale Head and Neck Specialized Program of Research Excellence (SPORE) Career Enhancement Program (CEP) Award. Arora will receive a one-year grant of $50,000 and eligibility for a second year of funding.

July 7, 2021

Fox Chase Receives Grant to Investigate Intersection of Nutrition and Cancer Care

PHILADELPHIA (July 7, 2021) - Researchers at Fox Chase Cancer Center have been awarded a $50,000 research grant from the MANNA Institute to measure the impact of a medically tailored meal program in patients with a non-terminal cancer diagnosis.

July 1, 2021

Fox Chase Cancer Center Welcomes Dr. Marcus Messmer

PHILADELPHIA (July 1, 2021) - Fox Chase Cancer Center is pleased to announce the hiring of Marcus Messmer, MD, who will join the Department of Hematology/Oncology as an assistant professor.

Pages

Connect with Fox Chase